Acrivon Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Acrivon is a clinical-stage precision oncology company with no approved products and no revenue to date.
Business context and development
The company’s lead candidate, ACR-368 (prexasertib), is in a Phase 2 trial across multiple tumor types, using its investigational OncoSignature test to identify patients predicted to respond. Acrivon also advanced ACR-2316, a preclinical WEE1/PKMYT1 inhibitor, and an earlier cell-cycle program.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $11.5 million | $9.8 million |
| General and administrative expense | $6.2 million | $4.6 million |
| Total operating expenses | $17.7 million | $14.4 million |
| Net loss | $16.5 million | $12.8 million |
| Net loss per share, basic and diluted | $0.73 | $0.58 |
| Net cash used in operating activities | $17.1 million | $11.4 million |
Operating expenses increased $3.3 million year over year, mainly from higher clinical and research activity, staffing, stock-based compensation, and public-company costs. Interest income fell to $1.4 million from $1.8 million. Profit margins are not meaningful because the company has no revenue.
At March 31, cash and cash equivalents were $24.6 million and short-term investments were $85.4 million, for $110.0 million combined. Current assets were $112.1 million and current liabilities were $9.0 million. Total liabilities were $12.5 million, including $4.4 million of operating lease liabilities; the filing reports no borrowings. Accumulated deficit was $132.9 million.
Management said the March 31 resources, together with the subsequent PIPE proceeds, were expected to fund operations and capital expenditures into the second half of 2026. This estimate depends on assumptions and may prove inaccurate.
Material developments, outlook, and risks
- After quarter-end, the April 2024 PIPE closed with $130.0 million in gross proceeds before fees and expenses. It comprised 8.235 million common shares and pre-funded warrants for up to 7.060 million shares; the warrants have a $0.001 exercise price. The financing may materially dilute existing holders.
- In April, Acrivon reported initial clinical data: confirmed objective response rate was 50% in 10 OncoSignature-positive ovarian and endometrial patients versus 0% in 16 negative patients (p=0.0038). These are early results from a small number of patients, not definitive evidence of efficacy.
- Management expects to file an IND for ACR-2316 in Q3 2024 and anticipates starting a clinical trial in Q4 2024. These are forward-looking targets.
- ACR-368 has FDA Fast Track designations for specified cancers, and its OncoSignature has Breakthrough Device designation for ovarian cancer patient identification. The assay has not received regulatory approval.
- The company expects continued losses and increased research, clinical, and administrative spending, and will need additional funding over time. Development, enrollment, regulatory, manufacturing, financing, intellectual-property, and commercialization risks could delay programs or require further capital.
- There were no material legal proceedings reported. Management concluded disclosure controls were effective at a reasonable-assurance level; no material change in internal control over financial reporting was reported for the quarter.
Most important facts for investors to verify
- Updated ACR-368 trial enrollment, follow-up, response durability, safety, and the performance of the OncoSignature in larger patient groups.
- Progress toward ACR-2316 IND submission and trial initiation, and whether the stated timelines remain achievable.
- Actual cash burn and whether the post-PIPE runway estimate through the second half of 2026 remains supportable as development spending evolves.
- Final PIPE-related costs, warrant exercises, resale activity, and the resulting share count and dilution.
- Regulatory progress and validation requirements for the OncoSignature assay, including any implications for ACR-368 development.